ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "essdai and Systemic manifestations"

  • Abstract Number: 1459 • 2019 ACR/ARP Annual Meeting

    Systemic Manifestations of Primary Sjögren Syndrome out of the ESSDAI Classification: Prevalence and Clinical Relevance in a Large International, Multi-ethnic Cohort of Patients

    Soledad Retamozo1, Nihan Acar-Denizli 2, Astrid Rasmussen 3, Ildiko Fanny Horváth 4, Chiara Baldini 5, Roberta Priori 6, Pulukool Sandhya 7, Gabriela Hernandez-Molina 8, Berkan Armagan 9, SONJA PRAPROTNIK 10, Marika Kvarnstrom 11, Roberto Gerli 12, Agata Sebastian 13, Roser Solans-Laqué 14, Maureen Rischmueller 15, Sandra G. Pasoto 16, Valeria Valim 17, Gunnel Nordmark 18, Aike Kruize 19, Takashi Nakamura 20, Benedikt Hofauer 21, Roberto Giacomelli 22, Virginia Fernandes Moça Trevisani 23, Valérie Devauchelle Pensec 24, Fabiola Atzeni 25, Tamer A Gheita 26, Sandra Consani-Fernández 27, Antonia Szántó 28, Kathy Sivils 3, Angelina Gattamelata 29, Debashish Danda 7, Levent Kilic 30, Elena Bartoloni 12, Stefano Bombardieri 31, Jorge Sánchez-Guerrero 32, Marie Wahren-Herlenius 11, Xavier Mariette 33, Manuel Ramos-Casals 34 and Pilar Brito-Zerón 35, 1Instituto De Investigaciones En Ciencias De La Salud, Univ. Nacional de Córdoba, Consejo Nacional de Investigaciones Científicas y Técnicas. Instituto Universitario de Ciencias Biomédicas de Córdoba, Córdoba, Argentina., Cordoba, Argentina, 2Department of Statistics, Faculty of Science and Letters, Mimar Sinan Fine Arts University, Istanbul, Turkey., Istanbul, Turkey, 3Arthritis and Clinical Immunology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, USA., Oklahoma, OK, 4Division of Clinical Immunology, Faculty of Medicine, University of Debrecen, Debrecen, Hungary., Debrecen, Hungary, 5Rheumatology Unit, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy, Pisa, Italy, 6Rheumatology Unit, Department of Internal Medicine and Medical Specialties, Sapienza University of Rome, Rome, Italy, Roma, Italy, 7Department of Clinical Immunology & Rheumatology, Christian Medical College & Hospital, Vellore, India., Vellore, India, 8Department of Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico, 9Department of Internal Medicine, Hacettepe University, Faculty of Medicine, Ankara, Turkey., Ankara, Turkey, 10Department of Rheumatology, University Medical Centre, Ljubljana, Slovenia., LJUBLJANA, Slovenia, 11Department of Medicine, Solna, Division of Experimental Rheumatology, Karolinska Institutet, and Karolinska University Hospital, Stockholm, Sweden., Stockholm, Sweden, 12Rheumatology Unit, Department of Medicine, University of Perugia, Perugia, Italy, Perugia, Italy, 13Department of Rheumatology and Internal Medicine, Wroclaw Medical Hospital, Wroclaw, Poland, Wroclaw, Poland, 14Department of Internal Medicine, Hospital Vall d'Hebron, Barcelona, Spain., Barcelona, Catalonia, Spain, 15Department of Rheumatology, The Queen Elizabeth Hospital and University of Adelaide, South Australia, Australia, 16Rheumatology Division, Hospital das Clinicas, Faculdade de Medicina da Universidade de Sao Paulo (HCFMUSP), Sao Paulo, Brazil., Sao Paulo, Brazil, 17Department of Medicine, Federal University of Espírito Santo, Vitória, Brazil., Vitória, Brazil, 18Rheumatology, Department of Medical Sciences, Uppsala University, Uppsala, Sweden., Uppsala, Sweden, 19Department of Rheumatology and Clinical Immunology, University Medical Center Utrecht, Utrecht, The Netherlands, Utrecht, Netherlands, 20Department of Immunology and Rheumatology, Division of Advanced Preventive Medical Sciences, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan., Nagasaki, Japan, 21Otorhinolaryngology, Head and Neck Surgery, Technical University Munich, Munich, Germany., Munich, Germany, 22Rheumatology Unit, Department of Biotechnological and Applied Clinical Science, School of Medicine, University of L'Aquila, L'Aquila, Italy, L'Aquila, Italy, 23Department of Evidence-Based Medicine, Brazilian Cochrane Centre, Federal University of São Paulo, Sao Paulo, Brazil, Sao Paulo, Brazil, 24University Hospital of Brest, Brest, France, 25Rheumatology Unit, University of Messina, Messina, Italy., Messina, Italy, 26Rheumatology Department, Kasr Al Ainy School of Medicine, Cairo University, Cairo, Egypt., Cairo, Egypt, 27Internal Medicine, Hospital Maciel, Montevideo, Uruguay. Universidad de la República (UdelaR) , Montevideo, Uruguay., Montevideo, Uruguay, 28Division of Clinical Immunology, Faculty of Medicine, University of Debrecen, Debrecen, Hungary, Debrecen, Hungary, 29Department of Internal Medicine and Medical Specialties, Rheumatology Clinic, Sapienza University of Rome, Rome, Italy, Rome, Italy, 30Hacettepe University, Faculty of Medicine, Department of Internal Medicine, Division of Rheumatology, Ankara, Turkey, 31Rheumatology Unit, University of Pisa, Pisa, Italy, Pisa, Italy, 32Immunology and Rheumatology Department, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán. México City, Mexico, Mexico, Mexico, 33Center for Immunology of Viral Infections and Autoimmune Diseases, Assistance Publique – Hôpitaux de Paris, Hôpitaux Universitaires Paris-Sud, Le Kremlin-Bicêtre, Université Paris Sud, INSERM, Paris, France, 34Department of Autoimmune Diseases, ICMiD. Sjögren Syndrome Research Group (AGAUR), Laboratory of Autoimmune Diseases Josep Font, IDIBAPS-CELLEX. Department of Medicine, University of Barcelona, Hospital Clínic, Barcelona, Spain., Barcelona, Spain, 35Sjögren Syndrome Research Group (AGAUR), Laboratory of Autoimmune Diseases Josep Font, IDIBAPS-CELLEX, Department of Autoimmune Diseases, ICMiD, University of Barcelona, Hospital Clínic. Autoimmune Diseases Unit, Department of Medicine, Hospital CIMA- Sanitas, Barcelona, Spain., Barcelona, Spain

    Background/Purpose: To analyse the frequency and characterize the systemic presentation of primary Sjögren syndrome (SjS) out of the ESSDAI classification in a large international, multi-ethnic…
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology